small-logo
ProfessionalsCapabilitiesInsights & NewsCareersLocations
About UsAlumniOpportunity & InclusionPro BonoCorporate Social Responsibility
Stay Connected:
facebookinstagramlinkedintwitteryoutube
Site Search
  • Professionals (203)
  • Capabilities (53)
  • Experience (34)
  • Insights & News (1,126)
  • Other Results (54)

Professionals 203 results

T. Reed Stephens
T. Reed Stephens
Partner
  • Washington, DC
Email
+1 202-282-5795
vCard

Partner

  • Washington, DC
Justin Levy
Justin Levy
Partner
  • New York
Email
+1 212-294-6677
vCard

Partner

  • New York
Nimalka Wickramasekera
Nimalka Wickramasekera
Partner
  • Los Angeles, 
  • Silicon Valley
Email
+1 213-615-1819
vCard

Partner

  • Los Angeles
  • Silicon Valley
View All Professionals

Capabilities 53 results

Industry

Life Sciences

Winston has been a major player in the life sciences industry for decades. We represent market-leading clients across this broad sector, including companies involved in pharmaceuticals, biologics, biosimilars, biotechnology, and medical devices. Our attorneys are seasoned practitioners—many of whom have technical degrees in areas key to the life sciences sector, including biology, chemistry, pharmacy, and biomedical engineering—and bring a unique understanding of the industry and perspective to our representations....Read more

Industry

Technology, Media & Telecommunications

Practice Area

Patent Litigation

Our Patent Litigation Practice is one of the country’s most active and highly regarded. Our seasoned patent litigators bring extensive courtroom experience to every matter we handle. According to Lex Machina, we are among the top three national patent defense firms in the country for number of appearances and cases filed, and we also were the top national defense firm for number of patent trials in the last five years (2018–2022)....Read more

Experience 34 results

Experience

|

April 23, 2025

Voyager Acquisition Corp. and VERAXA Biotech Announce Business Combination

Winston & Strawn represented Voyager Acquisition Corp. in its announced business combination agreement with VERAXA Biotech AG, a biopharmaceutical company developing next-generation antibody-based cancer therapies. The combination will result in VERAXA becoming a publicly traded company on Nasdaq under the ticker symbol “VERX”, with a pre-money equity valuation of $1.3 billion and up to $253 million in cash held in trust by Voyager. The transaction is expected to close in the fourth quarter of 2025, subject to regulatory and shareholder approvals....Read more

Experience

|

May 2, 2024

Winston Represented Industrial Opportunity Partners in Recapitalization of Transcendia Holdings

Winston represented its client Industrial Opportunity Partners (IOP), an Evanston, IL-based private equity firm, in a recapitalization transaction adding new capital and debt reduction for Transcendia Holdings, a Franklin Park, IL-based manufacturer and converter of custom engineered materials. The transaction will provide Transcendia with US$114M in new capital, eliminate more than $200M of the Company's debt, and further strengthen Transcendia's competitive position in the market with additional operating resources. Under the terms of the agreement, an investment fund managed by IOP and investment funds managed by Goldman Sachs Asset Management will lead the capital infusion and recapitalization, which has received unanimous support from the Company's existing second lien lenders and is further supported with a new first lien credit facility from General Atlantic Credit's Atlantic Park Fund. As a result of the transaction, IOP will assume majority ownership of Transcendia, while Goldman Sachs Asset Management, its existing equity sponsor, will maintain a significant minority stake....Read more

Experience

|

April 29, 2024

Winston advised the partners of BCF Life Sciences Group in its sale to Sparkfood

A Winston Paris team advised the partners of Diorren SAS, the holding company of BCF Life Sciences ("BCF"), in the sale of BCF Life Sciences Group to Sparkfood, SA, a subsidiary of the listed Sonae group....Read more
View All Experience

Insights & News 1,126 results

Capital Markets & Securities Law Watch

|

November 14, 2025

|

6 Min Read

Back in Business: What the SEC’s Post-Shutdown Guidance Means for Issuers and Underwriters

On November 13, 2025, following the end of the federal government shutdown, the Securities and Exchange Commission (SEC) issued guidance that offers much‑needed clarity to issuers, underwriters, and advisors navigating filings made during and immediately after the shutdown. With more than 900 registration statements filed during the shutdown, questions quickly mounted regarding automatic effectiveness, the treatment of missing information under Rule 430A, acceleration mechanics, and the status of filings already in the review pipeline. The staff (the Staff) of the SEC’s Division of Corporation Finance (the Division) addressed these topics directly through a series of Questions and Answers. This alert explains the guidance, describes the practical implications for capital markets and M&A participants, and recommends near‑term steps to adapt filing and transaction timelines.

Client Alert

|

November 12, 2025

|

3 Min Read

Take Notice: California Expands Healthcare Transaction Notification Regime

Just five days after tightening restrictions on the corporate practice of medicine for hedge funds and private equity groups, on October 11, 2025, California Governor Gavin Newsom signed Assembly Bill 1415 (AB 1415) into law, expanding the types of entities and transactions that must be reported to the California Office of Health Care Affordability (OHCA) under the state’s healthcare transaction review law....Read more

Client Alert

|

November 11, 2025

|

3 Min Read

California Codifies Restrictions on Corporate Practice of Medicine and Other Private Equity Arrangements with Providers

On October 6, 2025, California Governor Gavin Newsom signed Senate Bill 351 (SB 351 or the Bill) into law, codifying certain prohibitions on the corporate practice of medicine and the use of certain restrictive covenants in the ownership and management of physician and dental practices. SB 351 aims to ensure that clinical decisions are exclusively made by licensed healthcare providers....Read more
View All Insights & News

Other Results 54 results

Law Glossary

What Is the DMCA?

Passed in 1998 and implemented in 2000, the Digital Millennium Copyright Act (DMCA) updated U.S. law to meet the requirements of international copyright treaties. The DMCA addresses challenging issues relating to uses of copyrighted material in the digital environment: it limits the liability of online service providers that meet certain conditions, while providing certain procedures for addressing online infringement; it prohibits circumvention of digital technologies that control or limit access to copyrighted works; and it prohibits the removal or modification of certain types of copyright management information contained in protected works. Title II of the DMCA (sometimes also referred to as the Online Copyright Infringement Liability Limitation Act, or OCILLA) is codified at Section 512, Title 17, of the United States Code....Read more

Site Content

What Is Emerging Technology?

Emerging technology is a term generally used to describe a new technology, but it may also refer to the continuing development of an existing technology; it can have slightly different meaning when used in different areas, such as media, business, science, or education. The term commonly refers to technologies that are currently developing, or that are expected to be available within the next five to ten years, and is usually reserved for technologies that are creating, or are expected to create, significant social or economic effects....Read more

Site Content

What Is Form 8-K Used For?

Form 8-K is a form required to be filed by registrants with the SEC when certain significant or “material” events occur, such as mergers and acquisitions, changes in management, and director resignations. The form generally must be filed with four business days of the event triggering disclosure....Read more
Logo
facebookinstagramlinkedintwitteryoutube

Copyright © 2025. Winston & Strawn LLP

AlumniCorporate Transparency Act Task ForceDEI Compliance Task ForceEqual Rights AmendmentLaw GlossaryThe Oval UpdateWinston MinutePrivacy PolicyCookie PolicyFraud & Scam AlertsNoticesSubscribeAttorney Advertising